The pathophysiology by which PNPLA3 contributes to NASH progression, and HCC development is not fully understood, but changes in lipid mobilization and aberrant HSCs activation have been identified using various experimental models [8]. This evidence concerns the gene PNPLA3 and hepatocellular carcinoma.